Results 41 to 50 of about 644 (148)
Asian Pacific Journal of Tropical Biomedicine, 2021 Objective: To investigate the antinociceptive effect of tingenone on inflammatory pain, as well as and the involvement of the cannabinoid receptors type 2 (CB2) and spinal microglia in this process.
Clarice C.V. Moura +3 more
doaj +1 more source
Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands [PDF]
British Journal of Pharmacology, 2008 Recent developments indicate that CB2 receptor ligands have the potential to become therapeutically important. To explore this potential, it is necessary to develop compounds with high affinity for the CB2 receptor and little affinity for the CB1 receptor.
A, Poso, J W, Huffman
openaire +2 more sources
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Research progress on the cannabinoid type-2 receptor and Parkinson’s disease
Frontiers in Aging NeuroscienceParkinson’s disease (PD) is featured by movement impairments, including tremors, bradykinesia, muscle stiffness, and imbalance. PD is also associated with many non-motor symptoms, such as cognitive impairments, dementia, and mental disorders.
Xiaoqi Yu +4 more
doaj +1 more source
BMC Cancer, 2018 Background The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system ...
Mohammed I. Khan +7 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade +7 more
wiley +1 more source
Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. [PDF]
PLoS ONE, 2015 The cannabinoid receptor 2 (CB2) is well known for its immune modulatory role. However, recent localisation of CB2 receptors in metabolically active tissue suggests that the CB2 receptor plays a significant role in energy homeostasis.
A N A Verty +4 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock +9 more
wiley +1 more source
Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease
Biomedicines, 2022 Celiac Disease (CD) represents an autoimmune disorder triggered by the exposure to gluten in genetically susceptible individuals. Recent studies suggest the involvement of macrophages in CD pathogenesis.
Chiara Tortora +8 more
doaj +1 more source
Cannabinoid Receptor CB2 Structure and CB2/Gi Signaling Mechanisms
The FASEB Journal, 2019 Cannabinoid receptor subtype 2 (CB2) is a class‐A family G protein‐coupled receptor (GPCR), located primarily in immune‐associated tissues and implicated in several immune and inflammatory diseases. Drugs targeting CB2 are predicted to be effective treatment alternatives for chronic neuropain and neuroinflammatory autoimmune ...
Changrui Xing +2 more
openaire +1 more source